Table 2

Drug resistance profile and received treatment with second-line drugs according to the different drug resistance patterns

Drug resistance pattern
MDRMDR+FQresMDR+INJresXDRTotal
SLDs and combinationsnNPer centnNPer centnNPer centnNPer centnNPer cent
Individual drugs
Injectables284367773241781351797552747050366176
 Amikacin243677104124111796107414556618
 Kanamycin23136763184144481792718742431566148
 Capreomycin8536723164139971795428743822666134
Fluorochinolones335367913741901761799868749261666193
 Ofloxacin301367822741661631799152747054366182
 Moxifloxacin203675164139411792332744310966116
 Levofloxacin43671041041792174196611
 Ciprofloxacin503671444110221791247458066112
PT/ETH319367873441831591798963748557566187
CS285367783441831641799266748954966183
PAS174367472841681361797655747439366159
Amoxicillin/clavulanate22367664115611793424743211366117
Linezolid13670241501790574786611
Clarithromycin2367164115817942743186613
Drug combinations
Type 1: regimen does not include INJ or FQ2436770410117913744286614
 Only FLDs2236760410117910740236613
 Only PT/ETH and/or PAS and/or CS23671041001790374456611
Type 2: regimen includes INJ9367244110217913744186613
 INJ only13670041001790074016610
 INJ+(PT/ETH or PAS or CS)836724411011791317442166612
 INJ+(PT/ETH or PAS or CS)+AMOX03670041011791074016610
Type 3: regimen includes FQ593671694122431792419742613066120
 FQ only13670141201790074026610
 FQ+(PT/ETH or PAS or CS)573671654112351792015742011266117
 FQ+(PT/ETH or PAS or CS)+AMOX136703417817944745166612
Type 4: regimen includes INJ and FQ275367752841681331797449746648566173
 INJ+FQ only23671041001790074026610
 INJ+FQ+(PT/ETH or PAS or CS)25236769254161811794529743938766159
 INJ+FQ+(PT/ETH or PAS or CS)+AMOX213676341752179292074279666115
  • AMOX, amoxicillin/clavulanate; CS, cycloserine; FLD, first-line drug FQ, fluoroquinolones; INJ, second-line injectable agents; MDR, multidrug resistance, no additional resistance to FQs or second-line injectable agents; PAS, p-aminosalicylic acid; PT/ETH, prothionamide/ethionamide; SLD, second-line drugs; XDR, extensive drug resistance.